Abstract: An assembly for facilitating ultrasonic visualization of positioning of a needle inserted into tissue includes a needle that is inserted into a sheath to define a transport channel between an outer surface of the needle and an inner surface of the sheath for transport of a fluid that is introduced into the sheath. The transport channel includes features that induce formation of ultrasonically visible features from the fluid. These features exit from the end of the sheath where they can be detected via ultrasonic imaging.

Abstract: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

Abstract: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

Abstract: A urethral suppository comprising a non-meltable base member sized to prevent insertion of the base member into the urethra, a non-meltable reinforcement projecting from the base member, and a meltable portion formed around a portion of the reinforcement. The meltable portion tapers along the reinforcement and is shaped for cooperating with the action of the periurethral musculature to retain the suppository within the urethra. A method of delivering one or more therapeutic agents to the female urinary tract, the method involving insertion of the urethral suppository into the urethra. A method for manufacturing a reinforced urethral suppository.

Abstract: Transluminal drug delivery method and device embodiments may include a urethral suppository formulated to treat diseases of the urethra and surrounding organs by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse affects on the glucosaminoglycan (GAG) barrier by the suppository may be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

Abstract: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

Abstract: A urethral suppository comprising a non-meltable base member sized to prevent insertion of the base member into the urethra, a non-meltable reinforcement projecting from the base member, and a meltable portion formed around a portion of the reinforcement. The meltable portion tapers along the reinforcement and is shaped for cooperating with the action of the periurethral musculature to retain the suppository within the urethra. A method of delivering one or more therapeutic agents to the female urinary tract, the method involving insertion of the urethral suppository into the urethra. A method for manufacturing a reinforced urethral suppository.